verITI-8 study design. ∗Indicates only patients who achieved tolerization entered the tapering and follow-up periods; † indicates patients with bleeding episodes during the tapering and follow-up periods were tested for recurrence of inhibitors and monitored for relapse. In the event of relapse, patients were to proceed to the end of treatment visit.